Tags

Type your tag names separated by a space and hit enter

Peptide microarray-based analysis of antibody responses to SARS-CoV-2 identifies unique epitopes with potential for diagnostic test development.
Eur J Immunol. 2021 07; 51(7):1839-1849.EJ

Abstract

Humoral immunity to the Severe Adult Respiratory Syndrome (SARS) Coronavirus (CoV)-2 is not fully understood yet but is a crucial factor of immune protection. The possibility of antibody cross-reactivity between SARS-CoV-2 and other human coronaviruses (HCoVs) would have important implications for immune protection but also for the development of specific diagnostic ELISA tests. Using peptide microarrays, n = 24 patient samples and n = 12 control samples were screened for antibodies against the entire SARS-CoV-2 proteome as well as the Spike (S), Nucleocapsid (N), VME1 (V), R1ab, and Protein 3a (AP3A) of the HCoV strains SARS, MERS, OC43, and 229E. While widespread cross-reactivity was revealed across several immunodominant regions of S and N, IgG binding to several SARS-CoV-2-derived peptides provided statistically significant discrimination between COVID-19 patients and controls. Selected target peptides may serve as capture antigens for future, highly COVID-19-specific diagnostic antibody tests.

Authors+Show Affiliations

JPT Peptide Technologies GmbH, Berlin, Germany.Institute for Molecular Diagnostics and Bioanalysis-IMDB gGmbH, Hennigsdorf, Germany. KH Labor GmbH, Bernburg, Germany. Medical Faculty, Institute of Experimental Internal Medicine, Otto von Guericke University, Magdeburg, Germany. Institute for Biochemistry and Biology, University of Potsdam, Potsdam, Germany.JPT Peptide Technologies GmbH, Berlin, Germany.KH Labor GmbH, Bernburg, Germany.KH Labor GmbH, Bernburg, Germany.KH Labor GmbH, Bernburg, Germany.KH Labor GmbH, Bernburg, Germany.JPT Peptide Technologies GmbH, Berlin, Germany.JPT Peptide Technologies GmbH, Berlin, Germany.Institute for Molecular Diagnostics and Bioanalysis-IMDB gGmbH, Hennigsdorf, Germany. in.vent GmbH, Hennigsdorf, Germany.Medical Faculty, Institute of Experimental Internal Medicine, Otto von Guericke University, Magdeburg, Germany.JPT Peptide Technologies GmbH, Berlin, Germany. Department of Clinical and Experimental Medicine, Brighton and Sussex Medical School, Brighton, UK.JPT Peptide Technologies GmbH, Berlin, Germany.Institute for Molecular Diagnostics and Bioanalysis-IMDB gGmbH, Hennigsdorf, Germany. KH Labor GmbH, Bernburg, Germany.JPT Peptide Technologies GmbH, Berlin, Germany.Institute for Molecular Diagnostics and Bioanalysis-IMDB gGmbH, Hennigsdorf, Germany. Institute for Biochemistry and Biology, University of Potsdam, Potsdam, Germany.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

33772767

Citation

Holenya, Pavlo, et al. "Peptide Microarray-based Analysis of Antibody Responses to SARS-CoV-2 Identifies Unique Epitopes With Potential for Diagnostic Test Development." European Journal of Immunology, vol. 51, no. 7, 2021, pp. 1839-1849.
Holenya P, Lange PJ, Reimer U, et al. Peptide microarray-based analysis of antibody responses to SARS-CoV-2 identifies unique epitopes with potential for diagnostic test development. Eur J Immunol. 2021;51(7):1839-1849.
Holenya, P., Lange, P. J., Reimer, U., Woltersdorf, W., Panterodt, T., Glas, M., Wasner, M., Eckey, M., Drosch, M., Hollidt, J. M., Naumann, M., Kern, F., Wenschuh, H., Lange, R., Schnatbaum, K., & Bier, F. F. (2021). Peptide microarray-based analysis of antibody responses to SARS-CoV-2 identifies unique epitopes with potential for diagnostic test development. European Journal of Immunology, 51(7), 1839-1849. https://doi.org/10.1002/eji.202049101
Holenya P, et al. Peptide Microarray-based Analysis of Antibody Responses to SARS-CoV-2 Identifies Unique Epitopes With Potential for Diagnostic Test Development. Eur J Immunol. 2021;51(7):1839-1849. PubMed PMID: 33772767.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Peptide microarray-based analysis of antibody responses to SARS-CoV-2 identifies unique epitopes with potential for diagnostic test development. AU - Holenya,Pavlo, AU - Lange,Paul Joris, AU - Reimer,Ulf, AU - Woltersdorf,Wolfram, AU - Panterodt,Thomas, AU - Glas,Michael, AU - Wasner,Mark, AU - Eckey,Maren, AU - Drosch,Michael, AU - Hollidt,Jörg-Michael, AU - Naumann,Michael, AU - Kern,Florian, AU - Wenschuh,Holger, AU - Lange,Robert, AU - Schnatbaum,Karsten, AU - Bier,Frank F, Y1 - 2021/05/07/ PY - 2021/02/11/revised PY - 2020/12/01/received PY - 2021/03/22/accepted PY - 2021/3/28/pubmed PY - 2021/7/15/medline PY - 2021/3/27/entrez KW - COVID-19 KW - SARS-CoV-2 KW - antibody KW - diagnostics KW - peptide microarray SP - 1839 EP - 1849 JF - European journal of immunology JO - Eur J Immunol VL - 51 IS - 7 N2 - Humoral immunity to the Severe Adult Respiratory Syndrome (SARS) Coronavirus (CoV)-2 is not fully understood yet but is a crucial factor of immune protection. The possibility of antibody cross-reactivity between SARS-CoV-2 and other human coronaviruses (HCoVs) would have important implications for immune protection but also for the development of specific diagnostic ELISA tests. Using peptide microarrays, n = 24 patient samples and n = 12 control samples were screened for antibodies against the entire SARS-CoV-2 proteome as well as the Spike (S), Nucleocapsid (N), VME1 (V), R1ab, and Protein 3a (AP3A) of the HCoV strains SARS, MERS, OC43, and 229E. While widespread cross-reactivity was revealed across several immunodominant regions of S and N, IgG binding to several SARS-CoV-2-derived peptides provided statistically significant discrimination between COVID-19 patients and controls. Selected target peptides may serve as capture antigens for future, highly COVID-19-specific diagnostic antibody tests. SN - 1521-4141 UR - https://www.unboundmedicine.com/medline/citation/33772767/Peptide_microarray_based_analysis_of_antibody_responses_to_SARS_CoV_2_identifies_unique_epitopes_with_potential_for_diagnostic_test_development_ L2 - https://doi.org/10.1002/eji.202049101 DB - PRIME DP - Unbound Medicine ER -